References
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. November 3, 2008. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed November 2009).
- Hughes A, Barber T, Nelson M. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect 2008;57:1–10.
- Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, . Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways. Abstract 7. 17th International HIV Drug Resistance Workshop. June 10–14, 2008, Sitges, Spain.
- Perez-Elias MJ, Gutierrez C, Lopez D, Muriel A, Moreno A, Casado JL, . Which is the best rule for calculating the number of ‘active drugs’ in HIV failing patients using new antiretroviral drugs (NAD)? Abstract WEPEB204. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19–22, 2009, Cape Town, South Africa.
- Miller MD, Danovich RM, Ke Y, Witmer M, Zhao J, Harvey C, . Longitudinal analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from P005 a phase II study in treatment-experienced patients. Abstract 6. 17th International HIV Drug Resistance Workshop. June 10–14, 2008, Sitges, Spain.
- McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, Chuck S, . Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase 2 study of elvitegravir (GS-9137). Abstract 9. 16th International HIV Drug Resistance Workshop. June 12–16, 2007, Barbados, West Indies.
- Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, . Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Anti-microb Agents Chemother 2008;52:1351–8.
- Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, . Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355–65.
- Ceccherini-Silberstein F, Armenia D, D’Arrigo R, Micheli V, Fabeni L, Meraviglia P, . Virological response and resistance in multi-experienced patients treated with raltegravir. Abstract 18. 17th International HIV Drug Resistance Workshop. June 10–14, 2008, Sitges, Spain.
- Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Bélec L, Weiss L, . Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008;9:765–70.
- Hatano H, Lampiris H, Huang W, Hoh R, Gupta S, Fransen S, . Virological and immunological outcomes in a cohort of patients failing integrase inhibitors. Abstract 10. 17th International HIV Drug Resistance Workshop. June 10–14, 2008, Sitges, Spain.
- Song I, Chen S, Lou Y, Borland J, Fujiwara T, Piscitelli S, . Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-1 infected patients. Abstract WEPEB250. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19–22, 2009, Cape Town, South Africa.
- Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, . Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharm Ther 2008;83:293–9.
- Ceccherini-Silberstein F. Impact of baseline HIV-1 integrase mutations with virological outcome in patients starting a raltegravir-containing regimen. 7th European HIV Drug Resistance Workshop. March 25–27, 2009, Stockholm, Sweden.